Fragmento

Article commented: Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H,Hwang SG, et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: Phase 2 trial. Hepatology 2016. Doi: 10.1002/hep.28693 [Epub ahead of print]. Comment: Cirrhosis is a leading cause of mortality worldwide, responsible for approximately 800,000 deaths in 2004.¹ Liver transplantation is the only efficacious option for end-stage liver cirrhosis. However, it is limited by donor availability, surgical complications, immunological rejection and high medical costs.² Because of these limitations, there has been a focus on therapies for advanced liver fibrosis. Abstinence from alcohol and the new therapies for cure of viral hepatitis C can halt the progression of fibrosis inchronic liver disease and in some cases lead to remodeling of the damaged liver with improvement in liver function. This has given hope that therapies can be created to help boost the regenerative and remodeling capacity of the liver in the absence of ongoing chronic injury.³ Furthermore, insome cases these therapies could be used as a means of bridging a patient with cirrhosis to liver transplantation if needed.

Palabras clave:

2016-10-21   |   258 visitas   |   Evalua este artículo 0 valoraciones

Vol. 15 Núm.5. Septiembre-Octubre 2016 Pags. 806-808 Ann Hepatol 2016; 15(5)